Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Bagg

Showing results (181-190 of 217) with videos related to

Pageof 22
Sort By:
Leukemia|July 1, 2021
Germline POT1 variants can predispose to myeloid and lymphoid neoplasmsTristan L Lim, David B Lieberman, Adam R Davis, et al.
American Journal of Hematology|April 7, 2020
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group studyHeesun J Rogers, Xiaoqiong Wang, Yan Xie, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
American Journal of Clinical Pathology|April 10, 2024
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group studyGenevieve M Crane, Julia T Geyer, Beenu Thakral, et al.
American Journal of Hematology|November 23, 2024
Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A Study From the Bone Marrow Pathology GroupTimothy J Kirtek, Weina Chen, Jaryse C Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
American Journal of Hematology|October 18, 2025
Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology GroupTimothy J Kirtek, Weina Chen, Jaryse C Harris, et al.
Haematologica|November 20, 2023
<i>STAT5B</i> mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophiliaC Cameron Yin, Wayne Tam, Serena M Walker, et al.
Science Translational Medicine|September 4, 2015
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaDavid L Porter, Wei-Ting Hwang, Noelle V Frey, et al.
Haematologica|November 8, 2011
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behaviorAlejandra Carvajal-Cuenca, Luz F Sua, Nhora M Silva, et al.
Pageof 22

Showing results (181-190 of 217) with videos related to

Sort By:
Pageof 22
Leukemia|July 1, 2021
Germline POT1 variants can predispose to myeloid and lymphoid neoplasmsTristan L Lim, David B Lieberman, Adam R Davis, et al.
American Journal of Hematology|April 7, 2020
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group studyHeesun J Rogers, Xiaoqiong Wang, Yan Xie, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
American Journal of Clinical Pathology|April 10, 2024
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group studyGenevieve M Crane, Julia T Geyer, Beenu Thakral, et al.
American Journal of Hematology|November 23, 2024
Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A Study From the Bone Marrow Pathology GroupTimothy J Kirtek, Weina Chen, Jaryse C Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
American Journal of Hematology|October 18, 2025
Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology GroupTimothy J Kirtek, Weina Chen, Jaryse C Harris, et al.
Haematologica|November 20, 2023
<i>STAT5B</i> mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophiliaC Cameron Yin, Wayne Tam, Serena M Walker, et al.
Science Translational Medicine|September 4, 2015
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaDavid L Porter, Wei-Ting Hwang, Noelle V Frey, et al.
Haematologica|November 8, 2011
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behaviorAlejandra Carvajal-Cuenca, Luz F Sua, Nhora M Silva, et al.
Pageof 22